Stockscreener 앱 받기
4.65
19.23%
0.75
Sab Biotherapeutics Inc 주식(SABS)의 최신 뉴스
SABS FY2024 EPS Reduced by Brookline Capital Management - Defense World
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023) - Yahoo Finance
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
SAB Bio's Q3 Loss Widens to $10.3M Despite Progress in Diabetes Drug Trial - StockTitan
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire
Critical Comparison: Sana Biotechnology (NASDAQ:SANA) & SAB Biotherapeutics (NASDAQ:SABS) - Defense World
SAB Biotherapeutics Inc (SABS) Getting Ready To Launch, Waiting For The Long Term Buyers - Stocks Register
Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Declines By 12.7% - Defense World
Saba Capital Income & Opportunities Fund II (NYSE:SABA) Major Shareholder Sells $37,672.38 in Stock - Defense World
Metric Analysis: Cassava Sciences Inc (SAVA)’s Key Ratios in the Limelight - The Dwinnex
Healthy Upside Potential: Sabre Corp (SABR) - SETE News
Assembly Biosciences keeps Neutral rating after Phase 1a study results - Investing.com
DSMB endorses continuation of Alzheimer's drug trials - Investing.com India
Cassava Sciences Unusual Options Activity For September 23 - Benzinga
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely - Yahoo Finance
Renaissance Technologies LLC Lowers Stock Position in SBA Communications Co. (NASDAQ:SBAC) - Defense World
Sabre Corporation (SABR): Among the Worst AI Stocks To Buy Under $10 - Yahoo Finance
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - Morningstar
SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Oppenheimer - Defense World
SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update - Defense World
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewswire
SAB Biotherapeutics (NASDAQ:SABS) Given “Buy” Rating at Chardan Capital - Defense World
SAB BIO Provides SAB-142 Clinical Trial Progress Update at - GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the - The Bakersfield Californian
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting - StockTitan
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - GlobeNewswire
SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated by Analysts at Oppenheimer - Defense World
How To Buy SAB Biotherapeutics, Inc. Stock Online in August 2024 - Traders Union
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG - Barchart
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, - openPR
Chardan Capital Analysts Boost Earnings Estimates for SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from HC Wainwright - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Chardan Capital - Defense World
SABS stock touches 52-week low at $2.3 amid market challenges - Investing.com
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - GlobeNewswire
Seasonal Influenza Treatment Market Size 2032 | SAb - openPR
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - GlobeNewswire
SAB BIO Appoints Lucy To as Chief Financial Officer - citybiz
SAB Biotherapeutics (NASDAQ:SABS) Trading Down 0.4% - American Banking and Market News
MarketBeat June market recap - SiouxFalls.Business
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021 - Quantisnow
Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics - Quantisnow
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS ... - Quantisnow
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda ... - Quantisnow
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human ... - Quantisnow
Reviewing SAB Biotherapeutics (NASDAQ:SABS) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Tenaya Therapeutics Announces Director Resignation By Investing.com - Investing.com
CSP Inc insider buys shares worth over $23,000 - Investing.com
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Broker Revenue Forecasts For SAB Biotherapeutics, Inc. (NASDAQ:SABS) Are Surging Higher - Yahoo New Zealand News
Need To Know: The Consensus Just Cut Its SAB Biotherapeutics, Inc. (NASDAQ:SABS) Estimates For 2022 - Yahoo Sport Australia
2.88%
2.65%
자본화:
|
볼륨(24시간):